S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
ASMB · Assembly Biosciences, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Assembly Biosciences Inc (ASMB)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$20.71
-0.45
(-2.13%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$20.71
$20.71
$21.93
52-WEEK RANGE
$20.71
$19.94
$39.70
What's happening
- ASMB is down 2.13% today, trading at $20.71. — Live quote
- Volume today (11,159) is well below its 3-month average of 275,430. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.20 actual vs. $-0.66 estimated (+69.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 4
Buy 6
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (11 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
ASMB
-40.72%
vs S&P 500
-53.12%
1-YEAR RETURN
ASMB
-31.55%
vs S&P 500
-46.91%
6-MONTH RETURN
ASMB
-32.37%
3-MONTH RETURN
ASMB
-19.55%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.20
Est. $-0.66
BEAT +69.7%
2026-04-26 (Q1 2026)
$-0.54
Est. $-0.58
BEAT +7.1%
2026-01-26 (Q4 2025)
$2.48
Est. $-0.66
BEAT +474.1%
2025-10-26 (Q3 2025)
$-0.72
Est. $-0.79
BEAT +8.9%
Valuation Measures & Ratios
Enterprise Value4$399.0M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)5.76
Price / Book71.78
EV4 / Revenue5.33
EV4 / EBITDA—
Profit Margin-0.06%
Operating Margin-11.75%
Return on Equity (ROE8)-0.02%
Return on Assets (ROA9)-0.02%
Avg Volume (3M)275,430
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $532.5M | $466.7M | $326.8M | $138.8M | $74.7M |
| P/E | -16.47 | -12.52 | -8.64 | -3.49 | -1.93 |
| Price/Book | 1.74 | 2.35 | 1.79 | 7.67 | 2.75 |
| EV/EBITDA | -12.64 | -10.09 | -7.12 | — | — |
| ROE | -10.58% | -18.78% | -20.70% | -219.78% | -142.48% |
| ROA | -9.77% | -15.83% | -15.76% | -49.25% | -39.04% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short2,822,392
Change from Prior Settlement+34.68%
% of Float—
Days to Cover (Short Ratio)6.83
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 38.9% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 10-Q, filed 2026-08-13; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -0.1%. Finnhub fundamentals ↗
- Trailing 52-week price return is -31.5%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ASMB
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$6.3M | -$11.4M | -$10.9M | -$11.1M | -$9.9M | -$11.0M | -$12.2M | -$10.7M |
| Net income | -$3.9M | -$9.1M | -$9.2M | -$10.2M | -$8.8M | -$9.6M | -$11.2M | -$9.1M |
| EPS (diluted) | $-0.20 | $-0.54 | $-0.72 | $-1.33 | $-1.17 | $-1.51 | $-1.98 | $-1.66 |
| EPS (basic) | $-0.20 | $-0.54 | $-0.72 | $-1.33 | $-1.17 | $-1.51 | $-1.98 | $-1.66 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $330.8M | $235.5M | $257.6M | $240.0M | $80.8M | $99.0M | $119.2M | $100.3M |
| Total liabilities | $25.2M | $36.9M | $50.8M | $57.3M | $62.7M | $71.9M | $85.8M | $74.3M |
| Stockholders' equity | $305.6M | $198.6M | $206.8M | $182.7M | $18.1M | $27.1M | $33.4M | $26.0M |
| Total current assets | $328.0M | $232.6M | $254.5M | $236.8M | $77.5M | $95.5M | $115.5M | $98.2M |
| Total current liabilities | $23.4M | $35.0M | $48.8M | $53.4M | $47.3M | $46.6M | $47.8M | $41.6M |
| Cash & equivalents | $32.3M | $31.1M | $58.5M | $22.5M | $24.0M | $23.4M | $38.3M | $28.5M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts receivable | $822.0K | $451.0K | $974.0K | $912.0K | — | — | $0 | $0 |
| Other current assets | — | — | — | — | — | — | — | — |
| Marketable securities (non-current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $315.0K | $214.0K | $221.0K | $229.0K | $219.0K | $251.0K | $284.0K | $316.0K |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | $312.0K | $312.0K | $312.0K | $312.0K | $312.0K | $312.0K | $312.0K | $312.0K |
| Accounts payable | $1.2M | $1.1M | $1.2M | $1.7M | $743.0K | $875.0K | $585.0K | $1.3M |
| Accrued liabilities | $3.3M | $2.7M | $7.7M | $5.7M | $3.4M | $2.3M | $6.9M | $4.8M |
| Deferred revenue (current) | $16.3M | $29.1M | $36.9M | $42.4M | $40.9M | $40.8M | $37.6M | $32.6M |
| Short-term debt | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $20.0K | $16.0K | $16.0K | $16.0K | $8.0K | $8.0K | $7.0K | $6.0K |
| Retained earnings | -$845.0M | -$841.1M | -$832.0M | -$854.1M | -$844.9M | -$834.7M | -$825.9M | -$815.6M |
| Accumulated other comprehensive income (loss) | -$623.0K | -$368.0K | -$41.0K | -$90.0K | -$279.0K | -$253.0K | -$211.0K | -$156.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.5M | -$22.1M | $14.2M | -$15.1M | -$16.8M | -$23.4M | -$407.0K | -$15.2M |
| Investing cash flow | -$92.1M | -$5.4M | $21.2M | -$158.3M | $17.0M | $6.6M | -$6.7M | $24.5M |
| Financing cash flow | $108.7M | $149.0K | $456.0K | $171.9M | $357.0K | $1.9M | $17.0M | $0 |
| Free cash flow | -$15.5M | -$22.1M | $14.2M | -$15.2M | -$16.8M | -$23.4M | -$407.0K | -$15.2M |
| Capital expenditures | $0 | $19.0K | $24.0K | $42.0K | $0 | $0 | $0 | $0 |
| Depreciation & amortization | $20.0K | $26.0K | $32.0K | $32.0K | $32.0K | $33.0K | $32.0K | $33.0K |
| Share-based compensation | $2.4M | $1.1M | $1.5M | $1.7M | $834.0K | $712.0K | $751.0K | $797.0K |
| Deferred income taxes | — | — | — | — | — | — | $0 | — |
| Change in accounts receivable | $371.0K | -$523.0K | $62.0K | $912.0K | $0 | $0 | $0 | $0 |
| Change in accounts payable | -$70.0K | -$42.0K | -$512.0K | $940.0K | -$132.0K | $290.0K | -$750.0K | $534.0K |
| Purchases of investments | $145.8M | $63.0M | $11.6M | $180.9M | $17.5M | $19.8M | $40.9M | $14.7M |
| Sales/maturities of investments | $53.8M | $57.6M | $32.8M | $22.7M | $34.5M | $26.4M | $34.2M | $39.2M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $72.3M | $28.5M | — | — | — |
| Operating income | -$12.1M | -$45.4M | -$64.6M | -$94.1M | -$132.7M |
| Net income | -$6.1M | -$40.2M | -$61.2M | -$93.1M | -$129.9M |
| EPS (diluted) | $-0.55 | $-6.69 | $-13.38 | $-23.08 | $-3.00 |
| EPS (basic) | $-0.55 | $-6.69 | $-13.38 | $-23.08 | $-3.00 |
| Operating margin | -$17 | -$159 | — | — | — |
| Net margin | -$8 | -$141 | — | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $257.6M | $119.2M | $136.8M | $101.8M | $191.1M |
| Total liabilities | $50.8M | $85.8M | $95.7M | $19.1M | $22.1M |
| Stockholders' equity | $206.8M | $33.4M | $41.1M | $82.7M | $168.9M |
| Total current assets | $254.5M | $115.5M | $133.8M | $97.0M | $154.2M |
| Total current liabilities | $48.8M | $47.8M | $39.2M | $16.3M | $16.1M |
| Cash & equivalents | $58.5M | $38.3M | $19.8M | $52.4M | $45.6M |
| Marketable securities (current) | — | — | — | — | — |
| Accounts receivable | $974.0K | $0 | $43.0K | $944.0K | $336.0K |
| Other current assets | — | — | — | — | — |
| Marketable securities (non-current) | — | — | — | — | — |
| Property, plant & equipment | $221.0K | $284.0K | $385.0K | $743.0K | $1.1M |
| Goodwill | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Other non-current assets | $312.0K | $312.0K | $312.0K | $889.0K | $1.7M |
| Accounts payable | $1.2M | $585.0K | $461.0K | $2.5M | $2.7M |
| Accrued liabilities | $7.7M | $6.9M | $5.7M | $7.3M | $6.9M |
| Deferred revenue (current) | $36.9M | $37.6M | $30.9M | — | — |
| Short-term debt | — | — | — | — | — |
| Common stock & paid-in capital | $16.0K | $7.0K | $5.0K | $4.0K | $48.0K |
| Retained earnings | -$832.0M | -$825.9M | -$785.7M | -$724.5M | -$631.4M |
| Accumulated other comprehensive income (loss) | -$41.0K | -$211.0K | -$81.0K | -$803.0K | -$419.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$41.1M | -$51.1M | $22.7M | -$84.5M | -$93.4M |
| Investing cash flow | -$113.5M | $40.2M | -$69.1M | $90.6M | $26.5M |
| Financing cash flow | $174.7M | $29.4M | $13.8M | $614.0K | $53.1M |
| Free cash flow | -$41.2M | -$51.1M | $22.5M | -$84.6M | -$96.5M |
| Capital expenditures | $66.0K | $28.0K | $255.0K | $102.0K | $3.1M |
| Depreciation & amortization | $129.0K | $129.0K | $450.0K | $498.0K | $466.0K |
| Share-based compensation | $4.7M | $3.1M | $5.1M | $6.6M | $5.2M |
| Deferred income taxes | — | $0 | $0 | $0 | -$2.5M |
| Change in accounts receivable | $974.0K | -$43.0K | -$901.0K | $608.0K | -$894.0K |
| Change in accounts payable | $586.0K | $124.0K | -$2.0M | -$166.0K | -$1.9M |
| Purchases of investments | $229.8M | $90.5M | $133.9M | $27.6M | $160.4M |
| Sales/maturities of investments | $116.4M | $130.7M | $65.0M | $88.0M | $175.2M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ASMB as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-06-16 to 2026-06-17
Recent transactions
- Insiders have net sold 29 shares over the last 182 days, across 0 purchases and 1 sale.
- Most recent: Bjorkquist Jeanette M (PFO and PAO) — Open market sale of 29 shares on 2026-06-17.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)29 sh(1 txns)
Net Shares-29
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Bjorkquist Jeanette M | PFO and PAO | Open market sale | 2026-06-17 | 29 |
| GILEAD SCIENCES, INC. | 10% owner | Grant / award | 2026-05-26 | 471,698 |
| White Nicole S | Chief Manufacturing Officer | Open market sale | 2026-03-30 | 188 |
| Gaggar Anuj | Chief Medical Officer | Grant / award | 2026-03-29 | 14,000 |
| Delaney William E IV | Chief Scientific Officer | Grant / award | 2026-03-29 | 14,000 |
| Okazaki Jason A | CEO and President | Grant / award | 2026-03-29 | 50,750 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-17 | Bjorkquist Jeanette M | PFO and PAO | Open market sale | 29 | $23.25 |
| 2026-05-26 | GILEAD SCIENCES, INC. | 10% owner | Grant / award | 471,698 | $26.50 |
| 2026-03-30 | Bjorkquist Jeanette M | PFO and PAO | Open market sale | 312 | $26.65 |
| 2026-03-30 | Bjorkquist Jeanette M | PFO and PAO | Open market sale | 16 | $27.49 |
| 2026-03-30 | White Nicole S | Chief Manufacturing Officer | Open market sale | 188 | $26.65 |
| 2026-03-30 | White Nicole S | Chief Manufacturing Officer | Open market sale | 9 | $27.49 |
| 2026-03-29 | Gaggar Anuj | Chief Medical Officer | Grant / award | 14,000 | $0.00 |
| 2026-03-29 | White Nicole S | Chief Manufacturing Officer | Grant / award | 14,000 | $0.00 |
| 2026-03-29 | Bjorkquist Jeanette M | PFO and PAO | Grant / award | 3,500 | $0.00 |
| 2026-03-29 | Delaney William E IV | Chief Scientific Officer | Grant / award | 14,000 | $0.00 |
| 2026-03-29 | Okazaki Jason A | CEO and President | Grant / award | 50,750 | $0.00 |
| 2026-03-29 | Bjorkquist Jeanette M | PFO and PAO | Grant / award | 6,500 | $0.00 |
| 2026-03-29 | White Nicole S | Chief Manufacturing Officer | Grant / award | 26,000 | $0.00 |
| 2026-03-29 | Gaggar Anuj | Chief Medical Officer | Grant / award | 26,000 | $0.00 |
| 2026-03-29 | Delaney William E IV | Chief Scientific Officer | Grant / award | 26,000 | $0.00 |
| 2026-03-29 | Okazaki Jason A | CEO and President | Grant / award | 94,250 | $0.00 |
| 2025-08-08 | GILEAD SCIENCES, INC. | 10% owner | Open market purchase | 2,295,920 | — |
| 2025-06-16 | Bjorkquist Jeanette M | PFO and PAO | Grant / award | 300 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:20 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-13 | View on SEC.gov → |
| 2026-06-18 | 4 | 2026-06-17 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-03-29 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-03-29 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-06-04 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-06-04 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-06-04 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-06-04 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-06-04 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-06-04 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-03-29 | View on SEC.gov → |
Recent news
Headlines about ASMB (Assembly Biosciences, Inc.). Links open the publisher — we don’t host full articles.
-
Assembly Biosciences (Nasdaq:ASMB) - Stock Analysis
Simply Wall Street · 2026-10-19 -
ASMB Dec 2026 12.500 call (ASMB261218C00012500) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-18 -
ASMB Nov 2026 25.000 call (ASMB261120C00025000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-18 -
ASMB Oct 2026 35.000 put (ASMB261016P00035000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-17 -
ASMB Nov 2026 22.500 put (ASMB261120P00022500) interactive stock chart
Yahoo Finance Australia · 2026-10-17 -
ASMB Nov 2026 30.000 put (ASMB261120P00030000) stock price, news, quote and history
Yahoo Finance Australia · 2026-10-17 -
ASMB261016P00025000 Interactive Stock Chart | ASMB Oct 2026 25.000 put Stock
Yahoo Finance · 2026-10-15 -
(ASMB) Movement as an Input in Quant Signal Sets
Stock Traders Daily · 2026-10-15
No headlines in this category right now — try “All”.